269 results on '"Gram, Hermann"'
Search Results
2. Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
3. Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
4. Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
5. Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
6. Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
7. Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
8. Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
9. Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
10. Generation of Rabbit Immune Libraries
11. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation
12. Expression of scFv Antibody Fragments in the Yeast Pichia pastoris
13. Generation of Rabbit Immune Libraries
14. Diffuse traumatic axonal injury in mice induces complex behavioural alterations that are normalized by neutralization of interleukin-1β
15. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis
16. Neutralization of Interleukin-1β following Diffuse Traumatic Brain Injury in the Mouse Attenuates the Loss of Mature Oligodendrocytes
17. In vitro Selection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library
18. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
19. Discovery and Development of Ilaris® for the Treatment of Cryopyrin-Associated Periodic Syndromes
20. Canakinumab (ILARIS®)
21. Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
22. A dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis
23. Interleukin-1β promotes atheroprotective changes of advanced atherosclerotic lesions in mice
24. Involvement of MicroRNA in Au-rich element-mediated m-RNA instability
25. Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.: 1692
26. MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorytation of p38α. (Reports)
27. Neutralization of interleukin-1β reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice
28. The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer
29. Neutralization of interleukin-1β modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice
30. The critical role of kinase activity of interleukin-1 receptor–associated kinase 4 in animal models of joint inflammation
31. Production of antibodies to canine IL-1β and canine TNF to assess the role of proinflammatory cytokines
32. dysregulated interleukin-18–interferon-γ–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
33. A Randomized Controlled Trial with an Anti-CCL2 (anti–Monocyte Chemotactic Protein 1) Monoclonal Antibody in Patients with Rheumatoid Arthritis
34. Secretion of scFv Antibody Fragments
35. Neutralization of Interleukin-1 beta following Diffuse Traumatic Brain Injury in the Mouse Attenuates the Loss of Mature Oligodendrocytes
36. Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
37. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis
38. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
39. Additional file 1: of Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
40. Mechanistic Insights to the Differential Effects of Interleukin-1 Isoforms on Experimental Atherosclerosis
41. An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome
42. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
43. Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis
44. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
45. Gene suppression by tristetraprolin and release by the p38 pathway
46. Commentary: "Preclinical characterization and clinical development of ILARIS (Canakinumab) for the treatment of autoinflammatory diseases"
47. Preclinical characterization and clinical development of ILARIS® (canakinumab) for the treatment of autoinflammatory diseases
48. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5′-Terminal Cap and Hairpin
49. A physical map of bacteriophage T4 including the positions of strong promoters and terminators recognized in vitro
50. The α-glucosyltransferases of bacteriophages T2, T4 and T6: A comparison of their primary structures
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.